Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
04.01.2024 - WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) - Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE therapeutics ...
United States Williamm Scholl Ellen Lubman Michael Atkins Melanoma Research Alliance Medical Advisory Panel Society For The Immunotherapy Of Cancer
Source: wallstreet-online.de